Last reviewed · How we verify
IXIARO®- Japanese Encephalitis vaccine
IXIARO is an inactivated Japanese encephalitis virus vaccine that stimulates the immune system to produce antibodies and cellular immunity against Japanese encephalitis virus.
IXIARO is an inactivated Japanese encephalitis virus vaccine that stimulates the immune system to produce antibodies and cellular immunity against Japanese encephalitis virus. Used for Prevention of Japanese encephalitis in travelers and residents of endemic areas in Asia and the Western Pacific.
At a glance
| Generic name | IXIARO®- Japanese Encephalitis vaccine |
|---|---|
| Sponsor | Medical University of Vienna |
| Drug class | Inactivated viral vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains inactivated (killed) Japanese encephalitis virus particles that trigger both humoral (antibody) and cell-mediated immune responses. Upon vaccination, the immune system recognizes viral antigens and develops protective immunity, enabling recognition and neutralization of live virus if exposure occurs. This provides protection against infection with Japanese encephalitis virus, which is transmitted by Culex mosquitoes in endemic regions of Asia and the Western Pacific.
Approved indications
- Prevention of Japanese encephalitis in travelers and residents of endemic areas in Asia and the Western Pacific
Common side effects
- Injection site pain, erythema, or swelling
- Headache
- Myalgia
- Fever
- Fatigue
Key clinical trials
- A Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis Messenger Ribonucleic Acid (mRNA) Vaccines (GBP560) in Healthy Adults (PHASE1, PHASE2)
- A Phase 1, First-in-human, Double-blinded, Randomized, Placebo-controlled Trial of a Zika Virus Purified Inactivated Vaccine (ZPIV) With Alum Adjuvant in Healthy Flavivirus-naive and Flavivirus-Primed Subjects. (PHASE1)
- Safety and Immunogenicity of the Japanese Encephalitis Vaccine IC51 (IXIARO®) in a Pediatric Population (PHASE3)
- Immunogenicity and Safety of the Japanese Encephalitis Vaccine IC51 (IXIARO®, JESPECT®) in a Pediatric Population in Non-endemic Countries (PHASE3)
- Long Term Immunity and Safety Following Vaccination With the JEV IC51 (IXIARO®, JESPECT®) in Pediatric Population In Non Endemic Countries. Uncontrolled, Ph3 FU-Study (PHASE3)
- Immune Responses After a Booster Immunisation With IXIARO® in Elderly Compared to Young Individuals. (PHASE4)
- Safety and Immunogenicity of Formulations of Dengue Vaccines in Healthy Flavivirus-Naïve Adults (PHASE2)
- Open-label, Randomized Study in a Pediatric Population in a JEV (Japanese Encephalitis Virus)-Endemic Country (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: